Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Severe allergic reactions Swelling of the face, lips, tongue, or throat with breathing difficulty
With ongoing clinical trials that continue to explore expanded indications, the class of GLP-1 drugs may soon revolutionize how metabolic diseases are being treated in China and around the world
A 2025 systematic review by Vasireddi and colleagues in HSS Journal screened 544 published papers and identified 36 meeting inclusion criteria 35 preclinical studies and only one human study: an uncontrolled, unblinded, retrospective case series of 12 patients receiving intra-articular BPC-157 for chronic knee pain, in which 7 of 12 (58%) reported self-described relief lasting more than 6 months, with no dose, effect size, or systematically collected adverse events published
Reshaping the Obesity Market Landscape GLP-1s, including widely recognized brand names Wegovy, Mounjaro, and Zepbound, have demonstrated profound weight-loss efficacy, often in the range of 1520% and are set to become the largest-selling drug class globally
US$ 26.12
US$ 21.19
US$ 29.62
US$ 28.26
US$ 21.29
US$ 24.25
